This report provides an overview of global clinical trials with a start date between January 1, 2022, and December 31, 2022.
Scope
- The clinical trials data used for these analyses were extracted from the publisher's Clinical Trials Database. The data included clinical trials with a start date between January 1, 2022 and December 31, 2022, which were captured in the database as of February 14, 2023. The trials were analyzed and segmented by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, molecule type, and top drug trials
Reasons to Buy
- Trends of 2022 trial landscape
- Comparison to 2021 trial landscape
- Can view top therapy areas,indications, geographies and sponsors for 2022 trials
- Designated focus on completed and terminated trials for 2022
- Spotlight on COVID-19
Table of Contents
- Executive Summary
- Introduction
- Global Clinical Trial Landscape in 2022
- Completed Trials in 2022
- Clinical Trial Terminations in 2022
- Spotlight on COVID-19 Clinical Trials for 2022
- Key Findings
- Appendix
Figures 1 and 2: Clinical trials by sponsor type, status and initiation/completion
Figures 3 and 4: Clinical trials, by phase and sponsor type
Figure 5: Single country and multinational trials
Figure 6: Clinical trials regions, by phase
Figure 7: Clinical trials regions, by phase and distribution
Figure 8: Clinical trials in top countries, by phase
Figure 9: Clinical trials in top countries, by phase and distribution
Figure 10: Clinical trials top therapy areas, by phase
Figure 11: Clinical trials top therapy areas, by phase and distribution
Figure 12: Pivotal/registration clinical trials top therapy areas, by phase
Figure 13: Clinical trials top indications, by phase
Figure 14: Clinical trials top indications, by phase and distribution
Figure 15: Pivotal/registration clinical trials top indications, by phase
Figure 16: Clinical trials top industry sponsors, by phase
Figure 17: Clinical trials top non-industry sponsors, by phase
Figure 18: Pivotal/registration clinical trials top industry sponsors, by phase
Figure 19: Completed trials endpoint status, by sponsor type
Figures 20 and 21: Completed trials endpoint status, by sponsor type and phase
Figure 22: Pivotal/registration industry-sponsored trials endpoint status, by phase
Figure 23: Completed clinical trials top sponsors, by phase
Figure 24: Top completed drugs, by clinical trial count
Figures 25 and 26: Terminated trials, by phase and reason
Figure 27: Terminated clinical trials top therapy areas, by phase
Figure 28: Terminated clinical trials top indications, by phase
Figure 29: Terminated clinical trials for sponsors, by phase
Figure 30: Clinical trials for COVID-19, by status and sponsor type
Figure 31: Clinical trials for COVID-19, by phase
Figure 32: Clinical trials for COVID-19, by top industry sponsors
Figure 33: Clinical trials for COVID-19, by top non-industry sponsors
Figures 34 and 35: Clinical trials for COVID-19, by molecule type and phase
Figures 36 and 37: Virtual trial components
